Anti-tremor and cell cycle responses in KB celIs treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin

International Journal of Oncology

Volumn 9, Issue 2, 1996, Pages 217-224

  Prewett, Marie ^a   Rockwell, Patricia ^a   Rose, Caroline ^a   Goldstein, Neil I ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Cell cycle; Cisplatin; EGFR; Monoclonal antibody; Xenografts

Indexed keywords

CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL STRAIN KB; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0030054907     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Modjtahedi H and Dean C: The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (Review). Int J Oncol 4: 277-296, 1994.
2. Ullrich A and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990.
3. Neal DE, Marsh C, Bennett MK, Abel PD, Hall RR, Sainbury JRC and Harris A: Epidermal-growth factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1: 268-366, 1985.
4. Sainsbury JRC, Farndon JR, Sherbert GV and Harris AL: Epidermal-growth factor receptors and oestrogen receptors in human breast cancer. Lancet 1: 364-366, 1985.
5. Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47: 87-96, 1991.
6. Perez-Soler R, Donato NJ, Shin DM, Rosenblum MG, Zhang H-Z, Tornos C, Brewer H, Chan JC, Lee JS, Hong WK and Murray JL: Tumor epidermal growth factor receptor studies in patients with non-small cell lung carcinoma or head and neck cancer treated with monoclonal antibody RG 83852. J Clin Oncol 12: 703-739, 1994.
7. Ethier S: Growth factor synthesis and human breast cancer progression. J Natl Cancer Inst 87: 964-973, 1995.
8. Scher HI, Sarkas A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J and Cordon-Cardo C: Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor (in the progression of prostatic neoplasms. Clin Cancer Res 1: 545-550, 1995.
9. Modjtahedi H, Eccles S, Sandle J, Box G, Titley J and Dean C: Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res 54: 1695-1701, 1994.
10. Wu X, Fan Z, Masui H, Rosen N and Mendelsohn J: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95: 897-1905, 1995.
11. Kawamoto T, Sato JD, Polikoff J, Sato GH and Mendelsohn J: Growth stimulation of A431 cells by EGF: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 80: 1134-1337, 1983.
12. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA and Mueller BM: Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 37: 343-349, 1993.
13. Goldstein NI, Prewett M, Zuklys K, Rockwell P and Mendelsohn J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1: 1311-1318, 1995.
14. Masui H, Kawamoto T, Sato JD, Wolff B, Sato G and Mendelsohn J: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44: 1002-1007, 1984.
15. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J and Sela M: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80: 1605-1611, 1988.
16. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller Jr WH and Mendelsohn J: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85: 1327-1333, 1983.
17. Fan Z, Baselga J, Masui H and Mendelsohn J: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 xenografts. Cancer Res 53: 4637-4642, 1993.
18. Telford WG, King LE and Fraker PJ: Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry. Cytometry 13: 137-143, 1992.
19. Rockwell P, Neufeld G, Glassman A, Caron D and Goldstein N: In vitro neutralization of vascular endothelial growth factor activation of flk-1 by a monoclonal antibody. Mol Cell Differ 3: 91-109, 1995.
20. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS and Berger WH: Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors. Cancer Res 47: 707-712, 1987.
21. Gu Y, Rosenblatt J and Morgan DO: Cell cycle regulation of Cdk2 activity by phosphorylation of thr160 and tyr15. EMBO J 11: 3995-4005, 1992.
22. Ciechanover A: The ubiquitin-proteasome proteolytic pathway. Cell 79: 13-21, 1994.
23. Glotzer M, Murray AW and Kirschner MW: Cyclin is degraded by the ubiquitin pathway. Nature 349: 132-138, 1991.
24. Hunter T and Pines J: Cyclins and cancer II: cyclin D and Cdk inhibitors come of age. Cell 79: 573-582, 1994.
25. Meikrantz W, Gisselbrecht S, Tam SW and Schlegel R: Activation of cyclin A-dependent protein kinases during apoptosis. Proc Natl Acad Sci USA 91: 3754-3758, 1994.
26. Hoang AT, Cohen KJ, Barrett JF, Bergstrom DA and Dang CV: Participation of cyclin A in wye-induced apoptosis. Proc Natl Acad Sci USA 91: 6875-6879, 1994.
27. Bortner DM and Rosenberg MP: Overexpression of cyclin A in the mammary glands of transgenic mice results in the induction of nuclear abnormalities and increased apoptosis. Cell Growth Differ 6: 1579-1589, 1995.
28. Demarcq C, Bunch RT, Creswell D and Eastman A: The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ 5: 983-993, 1994.
29. Fan S, Smith ML, Rivet II DJ, Duba D, Zhan Q, Kohn KW, Fornace Jr AJ and O'Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654, 1995.
30. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279, 1991.
31. Sherr CJ: Mammalian G1 cyclins. Cell 73: 1059-1065, 1993.
32. 1 phase progression: cycling on cue. Cell 79: 551-555, 1994.
33. Weinberg RA: The retinoblastoma protein and the cell cycle. Cell 81: 323-330, 1995.
34. Strauss M, Lukas J and Bartek J: Unrestricted cell cycling and cancer. Nature Med 1: 1245-1246, 1995.
35. Ajchenbaum F, Ando K, De Caprio JA and Griffin JD: Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes. J Biol Chem 268: 4113-4119, 1993.
36. Won K, Xiong Y, Beach D and Gilman MZ: Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc Natl Acad Sci USA 89: 9910-9914, 1992.
37. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ and Kato JY: D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14: 2066-2076, 1994.
38. 1 phase of the cell cycle. Cell 65: 701-713, 1991.
39. Winston JT and Pledger WJ: Growth factor regulation of cyclin D1 mRNA expression through protein synthesis-dependent and -independent mechanisms. Mol Biol Cell 4: 1133-1144, 1993.
40. Divgi CR, Welt S, Kris M, Real FX, Yeh SDJ, Gralla R, Merchant B, Schweighart S, Unger M, Larson SM and Mendelsohn J: Phase I and imaging trial of indium-111 labeled anti-EGF receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 83: 97-104, 1991.